Matches in SemOpenAlex for { <https://semopenalex.org/work/W1540882011> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W1540882011 endingPage "0" @default.
- W1540882011 startingPage "0" @default.
- W1540882011 abstract "Lapatinib: the evidence for its therapeutic value in metastatic breast cancer Andrew ThomsonCore Medical Publishing, Knutsford, UKIntroduction: Breast cancer is the most common cancer affecting women. Many patients ultimately progress to metastatic disease and optimal management of this disease remains a significant therapeutic challenge. Lapatinib, a dual tyrosine kinase inhibitor, is in clinical development for treatment of this disease. Aims: The objective of this article is to review the published evidence for the treatment of metastatic breast cancer with lapatinib, and assess its therapeutic potential.Evidence review: Most evidence has appeared in meeting abstract reports of phase I and II studies in healthy volunteers and cancer patients. Four studies have included patients with exclusively breast cancer. Complete and partial responses and stable disease has been reported in some patients. Emerging evidence indicates that complete and partial responses can be achieved in some patients with metastatic breast cancer. Lapatinib appears to be well tolerated in cancer patients and the maximum tolerated dose is in the region of 1800 mg/day. In addition, it has been used in combination with other cancer treatments. Five ongoing or planned phase II monotherapy and three phase III combination-therapy studies with lapatinib have been identified.Outcomes summary: The phase I and II studies reported to date have provided safety data and preliminary indications regarding efficacy. There is preliminary evidence that lapatinib can achieve objective response rates of 10–38% in patients with metastatic breast cancer. Patients with tumors overexpressing ErbB1 and/or ErbB2 are likely to benefit from lapatinib treatment. Key words: lapatinib, GW572016, metastatic breast cancer, signal transduction, tyrosine kinase inhibition" @default.
- W1540882011 created "2016-06-24" @default.
- W1540882011 creator A5074439012 @default.
- W1540882011 date "2005-06-01" @default.
- W1540882011 modified "2023-09-23" @default.
- W1540882011 title "Lapatinib: the evidence for its therapeutic value in metastatic breast cancer" @default.
- W1540882011 cites W1815740577 @default.
- W1540882011 cites W1967763477 @default.
- W1540882011 cites W1982729445 @default.
- W1540882011 cites W1999645465 @default.
- W1540882011 cites W2006720018 @default.
- W1540882011 cites W2024409851 @default.
- W1540882011 cites W2027355084 @default.
- W1540882011 cites W2085880972 @default.
- W1540882011 cites W2105189307 @default.
- W1540882011 cites W2112596743 @default.
- W1540882011 cites W2112720107 @default.
- W1540882011 cites W2114927528 @default.
- W1540882011 cites W2115007832 @default.
- W1540882011 cites W2119609398 @default.
- W1540882011 cites W2123206362 @default.
- W1540882011 cites W2142752401 @default.
- W1540882011 cites W2158863975 @default.
- W1540882011 cites W2167725758 @default.
- W1540882011 cites W2184278156 @default.
- W1540882011 cites W2264655007 @default.
- W1540882011 doi "https://doi.org/10.2147/ce.s7411" @default.
- W1540882011 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3321658" @default.
- W1540882011 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22500146" @default.
- W1540882011 hasPublicationYear "2005" @default.
- W1540882011 type Work @default.
- W1540882011 sameAs 1540882011 @default.
- W1540882011 citedByCount "1" @default.
- W1540882011 countsByYear W15408820112015 @default.
- W1540882011 crossrefType "journal-article" @default.
- W1540882011 hasAuthorship W1540882011A5074439012 @default.
- W1540882011 hasBestOaLocation W15408820111 @default.
- W1540882011 hasConcept C121608353 @default.
- W1540882011 hasConcept C126322002 @default.
- W1540882011 hasConcept C143998085 @default.
- W1540882011 hasConcept C2775930923 @default.
- W1540882011 hasConcept C2777329042 @default.
- W1540882011 hasConcept C2778820342 @default.
- W1540882011 hasConcept C2779134260 @default.
- W1540882011 hasConcept C2779786085 @default.
- W1540882011 hasConcept C530470458 @default.
- W1540882011 hasConcept C71924100 @default.
- W1540882011 hasConceptScore W1540882011C121608353 @default.
- W1540882011 hasConceptScore W1540882011C126322002 @default.
- W1540882011 hasConceptScore W1540882011C143998085 @default.
- W1540882011 hasConceptScore W1540882011C2775930923 @default.
- W1540882011 hasConceptScore W1540882011C2777329042 @default.
- W1540882011 hasConceptScore W1540882011C2778820342 @default.
- W1540882011 hasConceptScore W1540882011C2779134260 @default.
- W1540882011 hasConceptScore W1540882011C2779786085 @default.
- W1540882011 hasConceptScore W1540882011C530470458 @default.
- W1540882011 hasConceptScore W1540882011C71924100 @default.
- W1540882011 hasLocation W15408820111 @default.
- W1540882011 hasLocation W15408820112 @default.
- W1540882011 hasOpenAccess W1540882011 @default.
- W1540882011 hasPrimaryLocation W15408820111 @default.
- W1540882011 hasRelatedWork W1975238878 @default.
- W1540882011 hasRelatedWork W1991018829 @default.
- W1540882011 hasRelatedWork W2004505325 @default.
- W1540882011 hasRelatedWork W2169144202 @default.
- W1540882011 hasRelatedWork W2338354381 @default.
- W1540882011 hasRelatedWork W2944980276 @default.
- W1540882011 hasRelatedWork W2955569507 @default.
- W1540882011 hasRelatedWork W3091784252 @default.
- W1540882011 hasRelatedWork W4248880404 @default.
- W1540882011 hasRelatedWork W4362586374 @default.
- W1540882011 hasVolume "Volume 1-Issues 1 & 2" @default.
- W1540882011 isParatext "false" @default.
- W1540882011 isRetracted "false" @default.
- W1540882011 magId "1540882011" @default.
- W1540882011 workType "article" @default.